Reported Earlier, Immix Biopharma Secures $8M Funding From California Institute For Regenerative Medicine For CAR-T NXC-201 Trial In AL Amyloidosis
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma (NASDAQ: IMMX) has secured $8 million in funding from the California Institute for Regenerative Medicine to support the clinical development of its CAR-T therapy NXC-201 for treating relapsed/refractory AL Amyloidosis.
July 26, 2024 | 5:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma has received $8 million in funding from the California Institute for Regenerative Medicine to advance its CAR-T therapy NXC-201 for AL Amyloidosis. This funding will support clinical trials and could accelerate the development of this promising therapy.
The $8 million funding from a reputable institution like the California Institute for Regenerative Medicine is a significant boost for Immix Biopharma. It will support the clinical development of their CAR-T therapy NXC-201, potentially accelerating its path to market. This positive development is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100